Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the fourth
most common cancer among men in South Korea, where the prevalence of chronic hepatitis …

Hepatocellular carcinoma (HCC) accounts for the vast majority of primary liver cancer and
constitutes a major global health challenge. Tumor ablation with either radiofrequency …

Background & Aims Radiofrequency ablation (RFA) and ablative external beam
radiotherapy (ablative RT) are commonly used to treat small intrahepatic malignancies. We …

Artesunate (ART) has been indicated as a candidate drug for hepatocellular carcinoma
(HCC). Glucosylceramidase (GBA) is required for autophagic degradation. Whether ART …

The existence of inadequate ablation remains an important cause of treatment failure for
loco‐regional ablation therapies. Here, using a preclinical model, it is reported that …

Introduction: A switching monopolar no-touch radiofrequency ablation (RFA) technique is
used for small hepatocellular carcinoma (HCC); however, there have not been any …

Purpose To compare the long-term outcomes of combined transarterial chemoembolization
and radiofrequency ablation (TACE-RFA) with radiofrequency ablation (RFA) monotherapy …

Although hepatocellular carcinoma (HCC) is associated with a poor prognosis, management
of early-stage HCC is often successful with highly efficacious treatment modalities such as …

Background Radiofrequency ablation (RFA) is a first-line treatment for early-stage
hepatocellular carcinoma (HCC). However, the recurrence after RFA remains an urgent …

Tumor ablation has been widely applied in Asia, accounting for 44.65% of clinical studies
worldwide. We reviewed 5853 clinical studies to provide insight on the advance of tumor …